Printer Friendly

ELECTROMEDICS RECEIVES NIH RESEARCH AWARD FOR NEW INTRAVENOUS MEMBRANE OXYGENATOR /ALSO KNOWN AS AN ARTIFICIAL LUNG~

 ELECTROMEDICS RECEIVES NIH RESEARCH AWARD FOR NEW INTRAVENOUS
 MEMBRANE OXYGENATOR |ALSO KNOWN AS AN ARTIFICIAL LUNG~
 ENGLEWOOD, Colo., July 29 /PRNewswire/ -- Electromedics Inc. (NASDAQ: ELMD) today announced that the National Heart, Lung and Blood Institute division of the National Institutes of Health in Bethesda, Md. has awarded the company a Phase I SBIR grant under the direction of Principal Investigator Gary D. Reeder, director of research for Electromedics.
 This grant is for a research project in association with Brack Hattler, MD, Ph.D., a cardiothoracic surgeon at the University of Pittsburgh Medical Center in Pittsburgh, Penn. who is the inventor of a new type of Intravenous Membrane Oxygenator (IMO) also commonly referred as an artificial lung. Hattler, his research coordinator, Patricia Sawzik, Ph.D. and Harvey Borovetz, Ph.D., professor of bioengineering, will be working with Electromedics' Reeder to refine and optimize this new patented IMO device.
 This IMO concept by Hattler incorporates hollow fibers arranged around a centrally positioned polyurethane balloon. The balloon, controlled by a special intra-aortic balloon pump console, will be pulse inflated using helium gas. The pulsating effect of the balloon during inflation and deflation will assist in providing optimal blood flow around the hollow microporous fibers that have oxygen flowing through them. This makes this system unique and "dynamic" as compared to "static" IMO units that have no methods to improve blood movement around the oxygenating fiber tubes. Because of the increased efficiency the Hattler IMO unit can be made smaller and yet still offer optimum performance.
 A paper given at the American Society for Artificial Internal Organs in May and an article in the June 1, 1992 issue of ADVANCE for Respiratory Care Practitioners have resulted in numerous inquiries from physicians wanting to assist with clinical trials. Following these refinements, and the required approvals, human clinical trials are expected to be completed within the next three years. Electromedics owns all patents, rights and technology to the IMO device.
 Electromedics is a leader in the autotransfusion segment of the blood processing market with the second largest share, which is over one third of the United States autotransfusion market. The company also designs and manufactures blood conservation devices and related disposable devices for use in cardiovascular, orthopedic and other medium/high blood loss surgeries.
 -0- 7/29/92
 /CONTACT: F. James Lynch or Richard B. Carlock of Electromedics, 303-790-8700; or Scott A. Brooks of Carl Thompson Associates, 303-494-5472, for Electromedics/
 (ELMD) CO: Electromedics Inc. ST: Colorado IN: MTC SU:


BB -- DV003 -- 4583 07/29/92 11:38 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 29, 1992
Words:422
Previous Article:HADSON ENERGY RESOURCES COMMENCES AUSTRALIAN GAS SALES
Next Article:USA TODAY NAMES NEW MANAGER/NATIONAL ADVERTISING SALES FOR BASEBALL WEEKLY
Topics:


Related Articles
AVECOR CARDIOVASCULAR REPORTS FIRST QUARTER RESULTS AND ANNOUNCES SUBMISSION OF NEW OXYGENATOR TO FDA
AVECOR CARDIOVASCULAR REPORTS THIRD QUARTER LOSS
AVECOR CARDIOVASCULAR REPORTS 1993 FOURTH QUARTER, YEAR-END RESULTS
AVECOR CARDIOVASCULAR REPORTS LOSS NARROWED IN 1ST QUARTER OF 1994
AVECOR CARDIOVASCULAR REPORTS HIGHER SALES, SMALLER LOSS FOR 2ND QUARTER OF 1994
AVECOR CARDIOVASCULAR REPORTS PROFIT IN SECOND QUARTER
AVECOR CARDIOVASCULAR REPORTS THIRD QUARTER GAINS; ARTERIAL FILTER CLEARED FOR MARKETING BY FDA
AVECOR CARDIOVASCULAR REPORTS FIRST QUARTER RESULTS
Avecor Cardiovascular Reports 3rd Quarter Earnings
AVECOR Cardiovascular Reports 2nd Quarter Earnings

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters